Compare iShares Core S&P 500 ETF (IVV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs TransMedics Group Inc — how do they compare? iShares Core S&P 500 ETF trades at $776.2, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| IVV | TMDX | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $776.81 | $150.42 |
52-Week Low | $634.93 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $776.18, down 0.07% with a bullish technical outlook from moving averages but overbought RSI signals. Recent news highlights record highs and institutional activity, with JPMorgan raising its S&P 500 target to 8,000 amid strong earnings growth. The ETF shows resilience despite valuation concerns.
Outlook remains positive due to AI-driven earnings growth, but risks include high valuations and market volatility. Investors benefit from broad market exposure, yet should monitor inflation reports and geopolitical events that could trigger pullbacks.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
